Paula Cannon, PhD

Title(s)Distinguished Professor of Molecular Microbiology & Immunology, Stem Cell Biology & Regenerative Medicine and Biomedical Engineering
SchoolKeck School of Medicine of Usc
AddressHMR 413A 2011 Zonal Avenue
Health Sciences Campus
Los Angeles CA 90089
Phone+1 323 442 1510
vCardDownload vCard
    Other Positions
    Title(s)Associate Director of Cross School Programs for the MESH Academy

    Title(s)Special Advisor to the Provost


    Collapse Overview 
    Collapse Overview
    Cannon Lab Website: http://uscmmi.com/paulacannonlab

    Paula Cannon, PhD, is a Distinguished Professor of Microbiology at the Keck School of Medicine of USC, where she leads a research team that studies viruses, stem cells and gene therapy. She obtained her PhD from the University of Liverpool in the United Kingdom, and received postdoctoral training as an HIV scientist at both Oxford and Harvard universities. Although HIV remains the main focus of her work, she also studies highly pathogenic hemorrhagic fever viruses, including Ebola and Lassa fever viruses. Cannon has a long-standing interest in the development of gene therapy as a clinical approach to treating HIV infection, and her recent work in this area is aimed at disrupting the viral co-receptor, CCR5, using zinc finger nucleases (ZFNs). This approach is being evaluated in human hematopoietic stem cells to address whether such a therapy could result in a "functional cure" for AIDS patients. Cannon’s research is funded by both the National Institutes of Health and the California Institute for Regenerative Medicine.

    Collapse Research 
    Collapse Research Activities and Funding
    Reversing Immune Dysfunction for HIV-1 Eradication
    NIH UM1AI164561Aug 16, 2021 - Apr 30, 2026
    Role: Co-Principal Investigator
    Novel hematopoietic stem cell engineering and transplantation approaches for HIV cure
    NIH U19HL156247May 15, 2020 - Apr 30, 2025
    Role: Principal Investigator
    Targeted inactivation of HIV in CNS reservoirs
    NIH R01MH113457Apr 20, 2017 - Jan 31, 2022
    Role: Principal Investigator
    Next Generation HSC Gene Therapy for HIV Control and Eradication
    NIH U19HL129902Apr 1, 2015 - Mar 31, 2021
    Role: Principal Investigator
    HIV-specific nucleases to reservoir cells
    NIH R33AI110149Nov 21, 2013 - Feb 29, 2020
    Role: Principal Investigator
    HIV-specific nucleases to reservoir cells
    NIH R21AI110149Nov 21, 2013 - Feb 29, 2016
    Role: Principal Investigator
    Understanding how HIV-1 Vpu and HIV-2 Env stimulate virus release
    NIH R01AI068546Apr 1, 2006 - Mar 31, 2012
    Role: Principal Investigator
    Retroviral Vectors for Safe and Efficacious Gene Therapy
    NIH R42RR019834Jun 1, 2004 - Dec 30, 2009
    Role: Principal Investigator
    Retroviral Vectors for Safe and Efficacious Gene Therapy
    NIH R41RR019834Jun 1, 2004 - Nov 30, 2005
    Role: Principal Investigator
    ENTRY PATHWAY OF NEW WORLD CLADE B ARENAVIRUSES
    NIH R21AI055720Sep 1, 2003 - Aug 31, 2006
    Role: Principal Investigator
    Administrative Core
    NIH U19AI149676
    Role: Principal Investigator

    Collapse Featured Content 
    Collapse Twitter
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Correction: Limited potential of AAV-mediated gene therapy in transducing human mesenchymal stem cells for bone repair applications. Gene Ther. 2024 Sep; 31(9-10):527. Bougioukli S, Chateau M, Morales H, Vakhshori V, Sugiyama O, Oakes D, Longjohn D, Cannon P, Lieberman JR. PMID: 39090205.
      View in: PubMed   Mentions:    Fields:    
    2. Reprogramming human B cells with custom heavy-chain antibodies. Nat Biomed Eng. 2024 Jul 22. Rogers GL, Huang C, Mathur A, Huang X, Chen HY, Stanten K, Morales H, Chang CH, Kezirian EJ, Cannon PM. PMID: 39039240.
      View in: PubMed   Mentions:    Fields:    
    3. Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptides. J Virol. 2023 08 31; 97(8):e0068423. Llewellyn GN, Chen HY, Rogers GL, Huang X, Sell PJ, Henley JE, Cannon PM. PMID: 37555663; PMCID: PMC10506483.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    4. Reprogramming human B cells with custom heavy chain antibodies. Res Sq. 2023 Jul 17. Rogers GL, Huang C, Mathur A, Huang X, Chen HY, Stanten K, Morales H, Chang CH, Kezirian EJ, Cannon PM. PMID: 37503066; PMCID: PMC10371167.
      View in: PubMed   Mentions:
    5. Reprogramming human B cells with custom heavy chain antibodies. bioRxiv. 2023 Jun 30. Rogers GL, Huang C, Mathur A, Huang X, Chen HY, Stanten K, Morales H, Chang CH, Kezirian EJ, Cannon PM. PMID: 37425794; PMCID: PMC10327003.
      View in: PubMed   Mentions:
    6. SARS-CoV-2 Enters Human Leydig Cells and Affects Testosterone Production In Vitro. Cells. 2023 04 20; 12(8). Li L, Sottas CM, Chen HY, Li Y, Cui H, Villano JS, Mankowski JL, Cannon PM, Papadopoulos V. PMID: 37190107; PMCID: PMC10136776.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    7. Knockdown of Astrocytic Monocarboxylate Transporter 4 in the Motor Cortex Leads to Loss of Dendritic Spines and a Deficit in Motor Learning. Mol Neurobiol. 2022 Feb; 59(2):1002-1017. Lundquist AJ, Llewellyn GN, Kishi SH, Jakowec NA, Cannon PM, Petzinger GM, Jakowec MW. PMID: 34822124.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    8. The genome-editing decade. Mol Ther. 2021 11 03; 29(11):3093-3094. Cannon PM, Kiem HP. PMID: 34699779; PMCID: PMC8571477.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    9. Genome edited B cells: a new frontier in immune cell therapies. Mol Ther. 2021 11 03; 29(11):3192-3204. Rogers GL, Cannon PM. PMID: 34563675; PMCID: PMC8571172.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    10. Optimization of AAV6 transduction enhances site-specific genome editing of primary human lymphocytes. Mol Ther Methods Clin Dev. 2021 Dec 10; 23:198-209. Rogers GL, Huang C, Clark RDE, Seclén E, Chen HY, Cannon PM. PMID: 34703842; PMCID: PMC8517001.
      View in: PubMed   Mentions: 12  
    11. Cytoplasmic Tail Truncation of SARS-CoV-2 Spike Protein Enhances Titer of Pseudotyped Vectors but Masks the Effect of the D614G Mutation. J Virol. 2021 10 27; 95(22):e0096621. Chen HY, Huang C, Tian L, Huang X, Zhang C, Llewellyn GN, Rogers GL, Andresen K, O'Gorman MRG, Chen YW, Cannon PM. PMID: 34495700; PMCID: PMC8549521.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    12. Safe and Effective In Vivo Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development. Hum Gene Ther. 2021 01; 32(1-2):31-42. Cannon P, Asokan A, Czechowicz A, Hammond P, Kohn DB, Lieber A, Malik P, Marks P, Porteus M, Verhoeyen E, Weissman D, Weissman I, Kiem HP. PMID: 33427035; PMCID: PMC8917879.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    13. Rational Selection of CRISPR-Cas9 Guide RNAs for Homology-Directed Genome Editing. Mol Ther. 2021 Mar 03; 29(3):1057-1069. Tatiossian KJ, Clark RDE, Huang C, Thornton ME, Grubbs BH, Cannon PM. PMID: 33160457; PMCID: PMC7934447.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    14. Limited potential of AAV-mediated gene therapy in transducing human mesenchymal stem cells for bone repair applications. Gene Ther. 2021 12; 28(12):729-739. Bougioukli S, Chateau M, Morales H, Vakhshori V, Sugiyama O, Oakes D, Longjohn D, Cannon P, Lieberman JR. PMID: 32807899.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    15. Gene Editing Expands the Donor Pool for CCR5-Negative Stem Cell Transplants. Cell Stem Cell. 2019 12 05; 25(6):735-736. Cannon PM. PMID: 31809736.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    16. Reply to "Efficient Nuclease-free HR by Clade F AAV Requires High MOIs with High Quality Vectors". Mol Ther. 2019 12 04; 27(12):2061-2062. Rogers GL, Chen HY, Morales H, Cannon PM. PMID: 31735602; PMCID: PMC6904797.
      View in: PubMed   Mentions:    Fields:    Translation:Cells
    17. Homologous Recombination-Based Genome Editing by Clade F AAVs Is Inefficient in the Absence of a Targeted DNA Break. Mol Ther. 2019 10 02; 27(10):1726-1736. Rogers GL, Chen HY, Morales H, Cannon PM. PMID: 31540849; PMCID: PMC6822228.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    18. Humanized Mouse Model of HIV-1 Latency with Enrichment of Latent Virus in PD-1+ and TIGIT+ CD4 T Cells. J Virol. 2019 05 15; 93(10). Llewellyn GN, Seclén E, Wietgrefe S, Liu S, Chateau M, Pei H, Perkey K, Marsden MD, Hinkley SJ, Paschon DE, Holmes MC, Zack JA, Louie SG, Haase AT, Cannon PM. PMID: 30842333; PMCID: PMC6498059.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    19. Reprogramming the antigen specificity of B cells using genome-editing technologies. Elife. 2019 01 17; 8. Voss JE, Gonzalez-Martin A, Andrabi R, Fuller RP, Murrell B, McCoy LE, Porter K, Huang D, Li W, Sok D, Le K, Briney B, Chateau M, Rogers G, Hangartner L, Feeney AJ, Nemazee D, Cannon P, Burton DR. PMID: 30648968; PMCID: PMC6355199.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCells
    20. Protect NIH's DNA advisory committee. Science. 2018 10 26; 362(6413):409-410. Adelman ZN, Albritton LM, Boris-Lawrie K, Buchmeier MJ, Cannon P, Cho M, DiGiusto D, Donahue JK, Federoff HJ, Hammarskjold ML, Hardison AD, Hearing P, Lee B, Lee DA, Porteus MH, Ross LF, Ross SR, Wooley DP, Zoloth L. PMID: 30361364.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    21. HIV-1 infection of microglial cells in a reconstituted humanized mouse model and identification of compounds that selectively reverse HIV latency. J Neurovirol. 2018 04; 24(2):192-203. Llewellyn GN, Alvarez-Carbonell D, Chateau M, Karn J, Cannon PM. PMID: 29256041; PMCID: PMC5910454.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimalsCells
    22. Inhibition of 53BP1 favors homology-dependent DNA repair and increases CRISPR-Cas9 genome-editing efficiency. Nat Biotechnol. 2018 01; 36(1):95-102. Canny MD, Moatti N, Wan LCK, Fradet-Turcotte A, Krasner D, Mateos-Gomez PA, Zimmermann M, Orthwein A, Juang YC, Zhang W, Noordermeer SM, Seclen E, Wilson MD, Vorobyov A, Munro M, Ernst A, Ng TF, Cho T, Cannon PM, Sidhu SS, Sicheri F, Durocher D. PMID: 29176614; PMCID: PMC5762392.
      View in: PubMed   Mentions: 130     Fields:    Translation:HumansAnimalsCells
    23. Gene Therapy Approaches to Human Immunodeficiency Virus and Other Infectious Diseases. Hematol Oncol Clin North Am. 2017 10; 31(5):883-895. Rogers GL, Cannon PM. PMID: 28895854.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    24. Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression. Nat Commun. 2017 03 01; 8:14447. Kalkavan H, Sharma P, Kasper S, Helfrich I, Pandyra AA, Gassa A, Virchow I, Flatz L, Brandenburg T, Namineni S, Heikenwalder M, Höchst B, Knolle PA, Wollmann G, von Laer D, Drexler I, Rathbun J, Cannon PM, Scheu S, Bauer J, Chauhan J, Häussinger D, Willimsky G, Löhning M, Schadendorf D, Brandau S, Schuler M, Lang PA, Lang KS. PMID: 28248314; PMCID: PMC5337983.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    25. Clinical Applications of Genome Editing to HIV Cure. AIDS Patient Care STDS. 2016 12; 30(12):539-544. Wang CX, Cannon PM. PMID: 27854119; PMCID: PMC5144849.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    26. Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem/progenitor cells. Mol Ther Methods Clin Dev. 2016; 3:16067. DiGiusto DL, Cannon PM, Holmes MC, Li L, Rao A, Wang J, Lee G, Gregory PD, Kim KA, Hayward SB, Meyer K, Exline C, Lopez E, Henley J, Gonzalez N, Bedell V, Stan R, Zaia JA. PMID: 27900346; PMCID: PMC5102145.
      View in: PubMed   Mentions: 47  
    27. International AIDS Society global scientific strategy: towards an HIV cure 2016. Nat Med. 2016 08; 22(8):839-50. Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P, Chomont N, Douek D, Lifson JD, Lo YR, Kuritzkes D, Margolis D, Mellors J, Persaud D, Tucker JD, Barre-Sinoussi F, International AIDS Society Towards a Cure Working Group, Alter G, Auerbach J, Autran B, Barouch DH, Behrens G, Cavazzana M, Chen Z, Cohen ÉA, Corbelli GM, Eholié S, Eyal N, Fidler S, Garcia L, Grossman C, Henderson G, Henrich TJ, Jefferys R, Kiem HP, McCune J, Moodley K, Newman PA, Nijhuis M, Nsubuga MS, Ott M, Palmer S, Richman D, Saez-Cirion A, Sharp M, Siliciano J, Silvestri G, Singh J, Spire B, Taylor J, Tolstrup M, Valente S, van Lunzen J, Walensky R, Wilson I, Zack J. PMID: 27400264; PMCID: PMC5322797.
      View in: PubMed   Mentions: 261     Fields:    Translation:Humans
    28. Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment. AIDS Patient Care STDS. 2016 07; 30(7):291-306. Woodham AW, Skeate JG, Sanna AM, Taylor JR, Da Silva DM, Cannon PM, Kast WM. PMID: 27410493; PMCID: PMC4948215.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    29. The clinical applications of genome editing in HIV. Blood. 2016 05 26; 127(21):2546-52. Wang CX, Cannon PM. PMID: 27053530; PMCID: PMC4882804.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    30. A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"? Pathog Immun. 2016; 1(1):154-164. Lederman MM, Cannon PM, Currier JS, June CH, Kiem HP, Kuritzkes DR, Lewin SR, Margolis DM, McCune JM, Mellors JW, Schacker TW, Sekaly RP, Tebas P, Walker BD, Douek DC. PMID: 27668293; PMCID: PMC5033048.
      View in: PubMed   Mentions: 24  
    31. Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat Biotechnol. 2015 Dec; 33(12):1256-1263. Wang J, Exline CM, DeClercq JJ, Llewellyn GN, Hayward SB, Li PW, Shivak DA, Surosky RT, Gregory PD, Holmes MC, Cannon PM. PMID: 26551060; PMCID: PMC4842001.
      View in: PubMed   Mentions: 162     Fields:    
    32. Determinants in HIV-2 Env and tetherin required for functional interaction. Retrovirology. 2015 Aug 07; 12:67. Exline CM, Yang SJ, Haworth KG, Rengarajan S, Lopez LA, Droniou ME, Seclen E, Cannon PM. PMID: 26248668; PMCID: PMC4528709.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    33. Novel Arenavirus Entry Inhibitors Discovered by Using a Minigenome Rescue System for High-Throughput Drug Screening. J Virol. 2015 Aug; 89(16):8428-43. Rathbun JY, Droniou ME, Damoiseaux R, Haworth KG, Henley JE, Exline CM, Choe H, Cannon PM. PMID: 26041296; PMCID: PMC4524252.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    34. Genome editing technologies: defining a path to clinic. Mol Ther. 2015 May; 23(5):796-806. Corrigan-Curay J, O'Reilly M, Kohn DB, Cannon PM, Bao G, Bushman FD, Carroll D, Cathomen T, Joung JK, Roth D, Sadelain M, Scharenberg AM, von Kalle C, Zhang F, Jambou R, Rosenthal E, Hassani M, Singh A, Porteus MH. PMID: 25943494; PMCID: PMC4427885.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansAnimalsCells
    35. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature. 2015 Mar 05; 519(7541):87-91. Gardner MR, Kattenhorn LM, Kondur HR, von Schaewen M, Dorfman T, Chiang JJ, Haworth KG, Decker JM, Alpert MD, Bailey CC, Neale ES, Fellinger CH, Joshi VR, Fuchs SP, Martinez-Navio JM, Quinlan BD, Yao AY, Mouquet H, Gorman J, Zhang B, Poignard P, Nussenzweig MC, Burton DR, Kwong PD, Piatak M, Lifson JD, Gao G, Desrosiers RC, Evans DT, Hahn BH, Ploss A, Cannon PM, Seaman MS, Farzan M. PMID: 25707797; PMCID: PMC4352131.
      View in: PubMed   Mentions: 175     Fields:    Translation:AnimalsCells
    36. HIV eradication--from Berlin to Boston. Nat Biotechnol. 2014 Apr; 32(4):315-6. Cannon PM, Kohn DB, Kiem HP. PMID: 24714473.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    37. Pre-clinical modeling of CCR5 knockout in human hematopoietic stem cells by zinc finger nucleases using humanized mice. J Infect Dis. 2013 Nov; 208 Suppl 2:S160-4. Hofer U, Henley JE, Exline CM, Mulhern O, Lopez E, Cannon PM. PMID: 24151324; PMCID: PMC3807977.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    38. Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases. Mol Ther. 2013 Jun; 21(6):1259-69. Li L, Krymskaya L, Wang J, Henley J, Rao A, Cao LF, Tran CA, Torres-Coronado M, Gardner A, Gonzalez N, Kim K, Liu PQ, Hofer U, Lopez E, Gregory PD, Liu Q, Holmes MC, Cannon PM, Zaia JA, DiGiusto DL. PMID: 23587921; PMCID: PMC3677314.
      View in: PubMed   Mentions: 96     Fields:    Translation:HumansAnimalsCells
    39. A systems biology starter kit for arenaviruses. Viruses. 2012 Dec; 4(12):3625-46. Droniou-Bonzom ME, Cannon PM. PMID: 23342371; PMCID: PMC3528283.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    40. Anti-tetherin activities of HIV-1 Vpu and Ebola virus glycoprotein do not involve removal of tetherin from lipid rafts. J Virol. 2012 May; 86(10):5467-80. Lopez LA, Yang SJ, Exline CM, Rengarajan S, Haworth KG, Cannon PM. PMID: 22398279; PMCID: PMC3347301.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    41. Substitutions in the glycoprotein (GP) of the Candid#1 vaccine strain of Junin virus increase dependence on human transferrin receptor 1 for entry and destabilize the metastable conformation of GP. J Virol. 2011 Dec; 85(24):13457-62. Droniou-Bonzom ME, Reignier T, Oldenburg JE, Cox AU, Exline CM, Rathbun JY, Cannon PM. PMID: 21976641; PMCID: PMC3233171.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsCells
    42. Lack of adaptation to human tetherin in HIV-1 group O and P. Retrovirology. 2011 Sep 28; 8:78. Yang SJ, Lopez LA, Exline CM, Haworth KG, Cannon PM. PMID: 21955466; PMCID: PMC3192746.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    43. Chemokine receptor 5 knockout strategies. Curr Opin HIV AIDS. 2011 Jan; 6(1):74-9. Cannon P, June C. PMID: 21242897; PMCID: PMC3066441.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansAnimalsCells
    44. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol. 2010 Aug; 28(8):839-47. Holt N, Wang J, Kim K, Friedman G, Wang X, Taupin V, Crooks GM, Kohn DB, Gregory PD, Holmes MC, Cannon PM. PMID: 20601939; PMCID: PMC3080757.
      View in: PubMed   Mentions: 350     Fields:    Translation:HumansAnimalsCells
    45. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. Retrovirology. 2010 Jun 07; 7:51. Hauser H, Lopez LA, Yang SJ, Oldenburg JE, Exline CM, Guatelli JC, Cannon PM. PMID: 20529266; PMCID: PMC2890665.
      View in: PubMed   Mentions: 114     Fields:    Translation:HumansCells
    46. Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. J Virol. 2010 Jul; 84(14):7243-55. Lopez LA, Yang SJ, Hauser H, Exline CM, Haworth KG, Oldenburg J, Cannon PM. PMID: 20444895; PMCID: PMC2898217.
      View in: PubMed   Mentions: 79     Fields:    Translation:HumansAnimalsCells
    47. Anti-tetherin activities in Vpu-expressing primate lentiviruses. Retrovirology. 2010 Feb 18; 7:13. Yang SJ, Lopez LA, Hauser H, Exline CM, Haworth KG, Cannon PM. PMID: 20167081; PMCID: PMC2831821.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansAnimalsCells
    48. Vpu-dependent block to incorporation of GaLV Env into lentiviral vectors. Retrovirology. 2010 Jan 26; 7:4. Christodoulopoulos I, Droniou-Bonzom ME, Oldenburg JE, Cannon PM. PMID: 20102634; PMCID: PMC2831008.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    49. Pseudotyping incompatibility between HIV-1 and gibbon ape leukemia virus Env is modulated by Vpu. J Virol. 2010 Mar; 84(6):2666-74. Lucas TM, Lyddon TD, Cannon PM, Johnson MC. PMID: 20042505; PMCID: PMC2826068.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    50. Stable transgene expression in primitive human CD34+ hematopoietic stem/progenitor cells, using the Sleeping Beauty transposon system. Hum Gene Ther. 2009 Dec; 20(12):1607-26. Sumiyoshi T, Holt NG, Hollis RP, Ge S, Cannon PM, Crooks GM, Kohn DB. PMID: 19689196; PMCID: PMC4094131.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    51. Investigation of clade B New World arenavirus tropism by using chimeric GP1 proteins. J Virol. 2010 Jan; 84(2):1176-82. Martin VK, Droniou-Bonzom ME, Reignier T, Oldenburg JE, Cox AU, Cannon PM. PMID: 19889757; PMCID: PMC2798354.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    52. Tissue-specific restriction of cyclophilin A-independent HIV-1- and SIV-derived lentiviral vectors. Gene Ther. 2008 Aug; 15(15):1079-89. Kahl CA, Cannon PM, Oldenburg J, Tarantal AF, Kohn DB. PMID: 18385767.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    53. New world clade B arenaviruses can use transferrin receptor 1 (TfR1)-dependent and -independent entry pathways, and glycoproteins from human pathogenic strains are associated with the use of TfR1. J Virol. 2008 Jan; 82(2):938-48. Flanagan ML, Oldenburg J, Reignier T, Holt N, Hamilton GA, Martin VK, Cannon PM. PMID: 18003730; PMCID: PMC2224602.
      View in: PubMed   Mentions: 77     Fields:    Translation:HumansAnimalsCells
    54. Receptor use by the Whitewater Arroyo virus glycoprotein. Virology. 2008 Feb 20; 371(2):439-46. Reignier T, Oldenburg J, Flanagan ML, Hamilton GA, Martin VK, Cannon PM. PMID: 17997467; PMCID: PMC2270610.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    55. Promoter choice for retroviral vectors: transcriptional strength versus trans-activation potential. Hum Gene Ther. 2007 Sep; 18(9):849-60. Weber EL, Cannon PM. PMID: 17767401.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    56. Differences in tropism and pH dependence for glycoproteins from the Clade B1 arenaviruses: implications for receptor usage and pathogenicity. Virology. 2007 Jul 20; 364(1):132-9. Oldenburg J, Reignier T, Flanagan ML, Hamilton GA, Cannon PM. PMID: 17397892; PMCID: PMC2743526.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    57. Receptor use by pathogenic arenaviruses. Virology. 2006 Sep 15; 353(1):111-20. Reignier T, Oldenburg J, Noble B, Lamb E, Romanowski V, Buchmeier MJ, Cannon PM. PMID: 16797051.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansAnimalsCells
    58. Recruitment of the adaptor protein 2 complex by the human immunodeficiency virus type 2 envelope protein is necessary for high levels of virus release. J Virol. 2006 Mar; 80(6):2924-32. Noble B, Abada P, Nunez-Iglesias J, Cannon PM. PMID: 16501101; PMCID: PMC1395462.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    59. Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production. J Virol. 2005 Mar; 79(6):3627-38. Abada P, Noble B, Cannon PM. PMID: 15731257; PMCID: PMC1075700.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansAnimalsCells
    60. Cytoplasmic tail of Moloney murine leukemia virus envelope protein influences the conformation of the extracellular domain: implications for mechanism of action of the R Peptide. J Virol. 2003 Jan; 77(2):1281-91. Aguilar HC, Anderson WF, Cannon PM. PMID: 12502845; PMCID: PMC140788.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansAnimalsCells
    61. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa. Nat Genet. 2002 Dec; 32(4):670-5. Chen M, Kasahara N, Keene DR, Chan L, Hoeffler WK, Finlay D, Barcova M, Cannon PM, Mazurek C, Woodley DT. PMID: 12426566.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCells
    62. Use of pseudotyped retroviral vectors to analyze the receptor-binding pocket of hemagglutinin from a pathogenic avian influenza A virus (H7 subtype). Virus Res. 2002 Feb 26; 83(1-2):43-56. Lin AH, Cannon PM. PMID: 11864740.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    63. Vesicular stomatitis virus G-pseudotyped lentivirus vectors mediate efficient apical transduction of polarized quiescent primary alveolar epithelial cells. J Virol. 2001 Dec; 75(23):11747-54. Borok Z, Harboe-Schmidt JE, Brody SL, You Y, Zhou B, Li X, Cannon PM, Kim KJ, Crandall ED, Kasahara N. PMID: 11689655; PMCID: PMC114760.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    64. Retroviral vectors bearing IgG-binding motifs for antibody-mediated targeting of vascular endothelial growth factor receptors. Int J Mol Med. 2001 Oct; 8(4):335-43. Masood R, Gordon EM, Whitley MD, Wu BW, Cannon P, Evans L, Anderson WF, Gill P, Hall FL. PMID: 11562769.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    65. Genomic stability of murine leukemia viruses containing insertions at the Env-3' untranslated region boundary. J Virol. 2001 Aug; 75(15):6989-98. Logg CR, Logg A, Tai CK, Cannon PM, Kasahara N. PMID: 11435579; PMCID: PMC114427.
      View in: PubMed   Mentions: 37     Fields:    Translation:AnimalsCells
    66. Sequences in the cytoplasmic tail of the gibbon ape leukemia virus envelope protein that prevent its incorporation into lentivirus vectors. J Virol. 2001 May; 75(9):4129-38. Christodoulopoulos I, Cannon PM. PMID: 11287562; PMCID: PMC114158.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansAnimalsCells
    67. Receptor-specific targeting mediated by the coexpression of a targeted murine leukemia virus envelope protein and a binding-defective influenza hemagglutinin protein. Hum Gene Ther. 2001 Mar 01; 12(4):323-32. Lin AH, Kasahara N, Wu W, Stripecke R, Empig CL, Anderson WF, Cannon PM. PMID: 11242525.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    68. Identification of regions in the Moloney murine leukemia virus SU protein that tolerate the insertion of an integrin-binding peptide. Virology. 2000 Mar 30; 269(1):7-17. Wu BW, Lu J, Gallaher TK, Anderson WF, Cannon PM. PMID: 10725193.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    69. Targeting retroviral vectors to CD34-expressing cells: binding to CD34 does not catalyze virus-cell fusion. Hum Gene Ther. 1999 Mar 01; 10(4):545-57. Benedict CA, Tun RY, Rubinstein DB, Guillaume T, Cannon PM, Anderson WF. PMID: 10094198.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    70. Role of variable regions A and B in receptor binding domain of amphotropic murine leukemia virus envelope protein. J Virol. 1998 Nov; 72(11):9101-8. Han JY, Zhao Y, Anderson WF, Cannon PM. PMID: 9765455; PMCID: PMC110327.
      View in: PubMed   Mentions: 19     Fields:    Translation:AnimalsCells
    71. Characterization of the proline-rich region of murine leukemia virus envelope protein. J Virol. 1998 Jul; 72(7):5383-91. Weimin Wu B, Cannon PM, Gordon EM, Hall FL, Anderson WF. PMID: 9620992; PMCID: PMC110165.
      View in: PubMed   Mentions: 34     Fields:    Translation:AnimalsCells
    72. Functional domains in the retroviral transmembrane protein. J Virol. 1998 Jul; 72(7):5392-8. Zhao Y, Zhu L, Benedict CA, Chen D, Anderson WF, Cannon PM. PMID: 9620993; PMCID: PMC110168.
      View in: PubMed   Mentions: 27     Fields:    Translation:AnimalsCells
    73. Mutational analysis of the fusion peptide of Moloney murine leukemia virus transmembrane protein p15E. J Virol. 1998 Feb; 72(2):1632-9. Zhu NL, Cannon PM, Chen D, Anderson WF. PMID: 9445069; PMCID: PMC124647.
      View in: PubMed   Mentions: 20     Fields:    Translation:AnimalsCells
    74. Identification of envelope protein residues required for the expanded host range of 10A1 murine leukemia virus. J Virol. 1997 Nov; 71(11):8103-8. Han JY, Cannon PM, Lai KM, Zhao Y, Eiden MV, Anderson WF. PMID: 9343159; PMCID: PMC192265.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    75. Structure-function studies of the human immunodeficiency virus type 1 matrix protein, p17. J Virol. 1997 May; 71(5):3474-83. Cannon PM, Matthews S, Clark N, Byles ED, Iourin O, Hockley DJ, Kingsman SM, Kingsman AJ. PMID: 9094619; PMCID: PMC191494.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    76. Functional analysis of the cytoplasmic tail of Moloney murine leukemia virus envelope protein. J Virol. 1997 May; 71(5):3613-9. Januszeski MM, Cannon PM, Chen D, Rozenberg Y, Anderson WF. PMID: 9094634; PMCID: PMC191509.
      View in: PubMed   Mentions: 51     Fields:    Translation:AnimalsCells
    77. Murine leukemia virus-based Tat-inducible long terminal repeat replacement vectors: a new system for anti-human immunodeficiency virus gene therapy. J Virol. 1996 Nov; 70(11):8234-40. Cannon PM, Kim N, Kingsman SM, Kingsman AJ. PMID: 8892960; PMCID: PMC190909.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    78. Conserved sequences in the carboxyl terminus of integrase that are essential for human immunodeficiency virus type 1 replication. J Virol. 1996 Jan; 70(1):651-7. Cannon PM, Byles ED, Kingsman SM, Kingsman AJ. PMID: 8523588; PMCID: PMC189861.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    79. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res. 1995 Feb 25; 23(4):628-33. Soneoka Y, Cannon PM, Ramsdale EE, Griffiths JC, Romano G, Kingsman SM, Kingsman AJ. PMID: 7899083; PMCID: PMC306730.
      View in: PubMed   Mentions: 289     Fields:    Translation:HumansAnimalsCells
    80. Human immunodeficiency virus type 1 integrase: effect on viral replication of mutations at highly conserved residues. J Virol. 1994 Aug; 68(8):4768-75. Cannon PM, Wilson W, Byles E, Kingsman SM, Kingsman AJ. PMID: 8035478; PMCID: PMC236416.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCells
    81. Analysis of Tat function in human immunodeficiency virus type 1-infected low-level-expression cell lines U1 and ACH-2. J Virol. 1994 Mar; 68(3):1993-7. Cannon P, Kim SH, Ulich C, Kim S. PMID: 8107261; PMCID: PMC236665.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    82. Inhibition of human immunodeficiency virus type 1 Tat-dependent activation of translation in Xenopus oocytes by the benzodiazepine Ro24-7429 requires trans-activation response element loop sequences. J Virol. 1994 Jan; 68(1):25-33. Braddock M, Cannon P, Muckenthaler M, Kingsman AJ, Kingsman SM. PMID: 8254735; PMCID: PMC236260.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    83. Human immunodeficiency virus-1 infection of the human promyelocytic cell line HL-60: high frequency of low-level infection and effect of subsequent cell differentiation. Blood. 1993 Jan 15; 81(2):437-45. Cannon PM, Tenen DG, Feinberg MB, Shin HS, Kim S. PMID: 8422463.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    84. Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodies. Proc Natl Acad Sci U S A. 1992 Nov 01; 89(21):10527-31. Luo L, Li Y, Cannon PM, Kim S, Kang CY. PMID: 1438241; PMCID: PMC50372.
      View in: PubMed   Mentions: 14     Fields:    Translation:AnimalsCells
    Paula's Networks
    Concepts (392)
    Derived automatically from this person's publications.
    _
    Co-Authors (31)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _